Identification

Name
Ramelteon
Accession Number
DB00980  (APRD01213)
Type
Small Molecule
Groups
Approved, Investigational
Description

Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.

Structure
Thumb
Synonyms
Not Available
External IDs
TAK-375 / TAK375
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RozeremTablet, film coated8 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-05-182017-09-20Us
RozeremTablet, film coated8 mg/1OralRebel Distributors2005-07-22Not applicableUs64764 0805 30 nlmimage10 191c8c94
RozeremTablet, film coated8 mg/1Oralbryant ranch prepack2005-07-22Not applicableUs
RozeremTablet, film coated8 mg/1OralAvera Mc Kennan Hospital2015-03-05Not applicableUs
RozeremTablet, film coated8 mg/1OralPhysicians Total Care, Inc.2006-08-01Not applicableUs
RozeremTablet, film coated8 mg/1OralCarilion Materials Management2005-07-22Not applicableUs
RozeremTablet, film coated8 mg/1OralTakeda2005-07-22Not applicableUs
International/Other Brands
Rozerem
Categories
UNII
901AS54I69
CAS number
196597-26-9
Weight
Average: 259.3434
Monoisotopic: 259.157228921
Chemical Formula
C16H21NO2
InChI Key
YLXDSYKOBKBWJQ-LBPRGKRZSA-N
InChI
InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1
IUPAC Name
N-{2-[(8S)-1H,2H,6H,7H,8H-indeno[5,4-b]furan-8-yl]ethyl}propanamide
SMILES
CCC(=O)NCC[[email protected]@H]1CCC2=C1C1=C(OCC1)C=C2

Pharmacology

Indication

For the treatment of insomnia characterized by difficulty with sleep onset.

Structured Indications
Pharmacodynamics

Ramelteon is the first selective melatonin agonist. It works by mimicking melatonin (MT), a naturally occuring hormone that is produced during the sleep period and thought to be responsible for the regulation of circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has a high affinity for the MT1 and MT2 receptors. The MT1 and MT2 receptors are located in the brain's suprachiasmatic nuclei (SCN),which is known as the body's "master clock" because it regulates the 24-hour sleep-wake cycle. Ramelteon has an active metabolite that is less potent but circulates in higher concentrations than the parent compound. The metabolite also has weak affinity for the 5HT2b receptor.

Mechanism of action

Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors, and lower selectivity for the MT3 receptor. Melatonin production is concurrent with nocturnal sleep, meaning that an increase in melatonin levels is related to the onset of self-reported sleepiness and an increase in sleep propensity. MT1 receptors are believed to be responsible for regulation of sleepiness and facilitation of sleep onset, and MT2 receptors are believed to mediate phase-shifting effects of melatonin on the circadian rhythm. While MT1 and MT2 receptors are associated with the sleep-wake cycle, MT3 has a completely different profile, and therefore is not likely to be involved in the sleep-wake cycle. Remelteon has no appreciable affinity for the gamma-aminobutyric acid (GABA) receptor complex or receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.

TargetActionsOrganism
AMelatonin receptor type 1A
multitarget
Human
AMelatonin receptor type 1B
multitarget
Human
Absorption

Rapid, total absorption is at least 84%.

Volume of distribution
  • 73.6 L
Protein binding

~82% (in human serum)

Metabolism

Hepatic

Route of elimination

Following oral administration of radiolabeled ramelteon, 84% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 88%. Less than 0.1% of the dose was excreted in urine and feces as the parent compound.

Half life

~1-2.6 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ramelteon is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Ramelteon can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ramelteon.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ramelteon.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Ramelteon can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ramelteon.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ramelteon.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ramelteon.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Amperozide.Experimental
ApalutamideThe serum concentration of Ramelteon can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Ramelteon can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon.Approved, Investigational
ArmodafinilThe metabolism of Ramelteon can be decreased when combined with Armodafinil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ramelteon.Approved
AtazanavirThe serum concentration of Ramelteon can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ramelteon can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Azaperone.Investigational, Vet Approved
AzelastineRamelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Ramelteon can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Ramelteon.Approved
BarbitalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ramelteon is combined with Benzyl alcohol.Approved
BoceprevirThe serum concentration of Ramelteon can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Ramelteon can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ramelteon can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ramelteon is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ramelteon.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Ramelteon.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Bupivacaine.Approved, Investigational
BuprenorphineRamelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ramelteon.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Ramelteon.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ramelteon is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ramelteon.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Ramelteon can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Ramelteon is combined with Canertinib.Investigational
CapecitabineThe serum concentration of Ramelteon can be increased when it is combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Ramelteon can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Ramelteon.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Ramelteon is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon.Approved
CeritinibThe serum concentration of Ramelteon can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Ramelteon.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Ramelteon can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ramelteon.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ramelteon.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ramelteon.Approved
CholecalciferolThe metabolism of Ramelteon can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Ramelteon can be decreased when combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Ramelteon can be decreased when combined with Citalopram.Approved
ClarithromycinThe serum concentration of Ramelteon can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Ramelteon can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Ramelteon.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Ramelteon.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ramelteon is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Ramelteon.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ramelteon.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Ramelteon can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ramelteon.Approved
CobicistatThe serum concentration of Ramelteon can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ramelteon.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Ramelteon.Approved, Investigational
CrizotinibThe metabolism of Ramelteon can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Ramelteon can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Ramelteon.Approved
Cyproterone acetateThe serum concentration of Ramelteon can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ramelteon can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Ramelteon can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ramelteon can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ramelteon can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Ramelteon can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ramelteon.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Ramelteon.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of sedation and somnolence can be increased when Ramelteon is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Ramelteon.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ramelteon.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ramelteon is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ramelteon.Approved, Illicit
DihydroergotamineThe metabolism of Ramelteon can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ramelteon can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ramelteon.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ramelteon.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Ramelteon can be increased when it is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Doxepin.Approved, Investigational
DoxycyclineThe metabolism of Ramelteon can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ramelteon is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Illicit
DronedaroneThe metabolism of Ramelteon can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ecopipam.Investigational
EfavirenzThe metabolism of Ramelteon can be decreased when combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Ramelteon.Approved, Investigational
EnzalutamideThe serum concentration of Ramelteon can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ramelteon can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Ramelteon can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Ramelteon can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ramelteon.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ramelteon.Approved, Investigational
EthanolRamelteon may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Ramelteon.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Ramelteon.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Ramelteon can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Ramelteon.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ramelteon.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Ramelteon.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flibanserin.Approved, Investigational
FloxuridineThe serum concentration of Ramelteon can be increased when it is combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fluanisone.Experimental
FluconazoleThe serum concentration of Ramelteon can be increased when it is combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fludiazepam.Approved, Illicit
FlumazenilFlumazenil may decrease the sedative activities of Ramelteon.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe serum concentration of Ramelteon can be increased when it is combined with Fluorouracil.Approved
FluoxetineThe metabolism of Ramelteon can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ramelteon.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ramelteon.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ramelteon.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ramelteon.Approved
FluvoxamineThe serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ramelteon can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ramelteon can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ramelteon can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Ramelteon can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ramelteon.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ramelteon is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ramelteon.Approved, Illicit, Investigational
GemfibrozilThe serum concentration of Ramelteon can be increased when it is combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Ramelteon is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon.Approved
HalothaneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Hexobarbital.Approved
HydrocodoneRamelteon may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ramelteon.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved
IdelalisibThe serum concentration of Ramelteon can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Iloperidone.Approved
ImatinibThe metabolism of Ramelteon can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Ramelteon can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Indiplon.Investigational
IsavuconazoleThe serum concentration of Ramelteon can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Ramelteon can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ramelteon.Approved, Vet Approved
IsoniazidThe metabolism of Ramelteon can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe metabolism of Ramelteon can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleThe serum concentration of Ramelteon can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ramelteon can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ramelteon.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Ramelteon can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ramelteon is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ramelteon.Approved
LidocaineThe metabolism of Ramelteon can be decreased when combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Ramelteon is combined with Lithium.Approved
LobeglitazoneThe metabolism of Ramelteon can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Ramelteon is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Ramelteon can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ramelteon.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ramelteon.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Ramelteon can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Ramelteon can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ramelteon.Approved
LuliconazoleThe serum concentration of Ramelteon can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ramelteon can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Ramelteon can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Ramelteon is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Ramelteon.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Ramelteon is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ramelteon.Approved
MethotrimeprazineRamelteon may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methylphenobarbital.Approved
MetyrosineRamelteon may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Ramelteon can be increased when it is combined with Mexiletine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ramelteon.Approved, Illicit
MidostaurinThe serum concentration of Ramelteon can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Ramelteon can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ramelteon is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
MirtazapineRamelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Ramelteon can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Ramelteon can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Ramelteon can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ramelteon.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ramelteon.Approved
NefazodoneThe serum concentration of Ramelteon can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Ramelteon can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ramelteon can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Ramelteon can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Ramelteon can be increased when it is combined with Nicardipine.Approved, Investigational
NilotinibThe metabolism of Ramelteon can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ramelteon.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ramelteon.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ramelteon.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ramelteon.Approved, Investigational
OlaparibThe metabolism of Ramelteon can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ramelteon.Approved
OmeprazoleThe metabolism of Ramelteon can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Ramelteon is combined with Opium.Approved, Illicit
OrphenadrineRamelteon may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ramelteon is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ramelteon can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ramelteon.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ramelteon is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ramelteon.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ramelteon.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Ramelteon can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ramelteon.Approved
PantoprazoleThe metabolism of Ramelteon can be decreased when combined with Pantoprazole.Approved
ParaldehydeRamelteon may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ramelteon.Approved, Vet Approved
PentobarbitalThe metabolism of Ramelteon can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved
PerazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ramelteon is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ramelteon.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ramelteon.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ramelteon is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Ramelteon can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Ramelteon can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ramelteon.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Piritramide.Approved, Investigational
PitolisantThe serum concentration of Ramelteon can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Ramelteon can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleRamelteon may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Ramelteon can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Prilocaine.Approved
PrimidoneThe metabolism of Ramelteon can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Ramelteon is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ramelteon.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ramelteon is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ramelteon.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ramelteon.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Raclopride.Investigational
RanolazineThe metabolism of Ramelteon can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ramelteon.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ramelteon.Approved, Investigational
RifabutinThe metabolism of Ramelteon can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Ramelteon can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ramelteon can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Ramelteon can be increased when combined with Rifaximin.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Romifidine.Vet Approved
RopiniroleRamelteon may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ropivacaine.Approved
RotigotineRamelteon may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Ramelteon can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ramelteon.Approved
SaquinavirThe serum concentration of Ramelteon can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Ramelteon can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Ramelteon.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ramelteon.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ramelteon is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Ramelteon can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ramelteon.Approved, Vet Approved
SildenafilThe metabolism of Ramelteon can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ramelteon can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Ramelteon can be increased when it is combined with Simeprevir.Approved
Sodium oxybateRamelteon may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
St. John's WortThe serum concentration of Ramelteon can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Ramelteon can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.Approved, Investigational
SulfadiazineThe serum concentration of Ramelteon can be increased when it is combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfisoxazoleThe serum concentration of Ramelteon can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Sultopride.Experimental
SuvorexantRamelteon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tasimelteon.Approved, Investigational
TelaprevirThe serum concentration of Ramelteon can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Ramelteon can be increased when it is combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ramelteon.Approved, Investigational
Tenofovir disoproxilThe metabolism of Ramelteon can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TeriflunomideThe serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrodotoxin.Investigational
ThalidomideRamelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Ramelteon can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Ramelteon is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ramelteon.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ramelteon.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Ramelteon can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Ramelteon.Approved, Investigational
TocilizumabThe serum concentration of Ramelteon can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe serum concentration of Ramelteon can be increased when it is combined with Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Ramelteon.Approved, Withdrawn
TopiramateThe metabolism of Ramelteon can be decreased when combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ramelteon.Approved, Investigational
TranylcypromineThe metabolism of Ramelteon can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ramelteon.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ramelteon is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Ramelteon is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ramelteon.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Ramelteon.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Ramelteon is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Ramelteon can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ramelteon can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Veralipride.Experimental
VerapamilThe metabolism of Ramelteon can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Ramelteon is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ramelteon is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Ramelteon can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Vortioxetine.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ramelteon is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ramelteon can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ramelteon is combined with Zolazepam.Vet Approved
ZolpidemRamelteon may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ramelteon.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ramelteon is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Ramelteon can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ramelteon.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Do not take with or immediately after a high-fat meal.

References

Synthesis Reference

Vinod Kumar Kansal, Dhirenkumar N. Mistry, Sanjay L. Vasoya, "Intermediates and processes for the synthesis of Ramelteon." U.S. Patent US20080242877, issued October 02, 2008.

US20080242877
General References
  1. Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265]
  2. Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178]
  3. Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703]
  4. Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111]
  5. Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650]
  6. Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19. [PubMed:18729542]
External Links
Human Metabolome Database
HMDB0015115
PubChem Compound
208902
PubChem Substance
46505923
ChemSpider
181000
BindingDB
50118470
ChEBI
109549
ChEMBL
CHEMBL1218
Therapeutic Targets Database
DAP000070
PharmGKB
PA164744896
IUPHAR
1356
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ramelteon
ATC Codes
N05CH02 — Ramelteon
FDA label
Download (2.36 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableSleeplessness1
1CompletedBasic ScienceMarijuana Dependence1
1CompletedPreventionSleeplessness1
2CompletedTreatmentChronic Insomnia2
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2CompletedTreatmentDrug Abuse1
2CompletedTreatmentSleep Apnea, Obstructive1
2CompletedTreatmentSleep Disorder1
2CompletedTreatmentSleep Disorders, Circadian Rhythm1
2CompletedTreatmentSleep Initiation and Maintenance Disorders2
2CompletedTreatmentMinor burns / Sleep1
2RecruitingPreventionAmnestic / Cognitive Disorders / Delayed Emergence From Anesthesia / Delirium / Delirium, Dementia / Delirium, Dementia, Amnestic, Cognitive Disorders1
2RecruitingTreatmentTobacco Use Disorders1
2TerminatedPreventionMigraine With Aura / Migraine Without Aura / Migraines1
3CompletedTreatmentBalance1
3CompletedTreatmentChronic Insomnia5
3CompletedTreatmentObstructive Sleep Apnea (OSA) / Sleeplessness1
3CompletedTreatmentSleep Initiation and Maintenance Disorders2
3CompletedTreatmentSleeplessness1
3CompletedTreatmentTransient Insomnia1
3TerminatedTreatmentAsthma Bronchial / Sleeplessness1
3TerminatedTreatmentBipolar Disorder (BD)1
3TerminatedTreatmentBipolar Disorder (BD) / Sleeplessness1
3TerminatedTreatmentChronic Insomnia1
3TerminatedTreatmentMajor Depressive Disorder (MDD) / Sleeplessness1
3Unknown StatusTreatmentChronic Insomnia / Gastroesophageal Reflux Disease1
3WithdrawnTreatmentBipolar Disorder (BD)1
4CompletedTreatmentADHD With Sleep Onset Insomnia1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentChronic Insomnia2
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentCircadian Dysregulation1
4CompletedTreatmentMajor Depressive Disorder (MDD) / Sleeplessness1
4CompletedTreatmentQuadriplegia / Sleep disorders and disturbances / Sleeplessness / Spinal Cord Injuries (SCI)1
4CompletedTreatmentREM Sleep Behavior Disorder1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders1
4CompletedTreatmentSeasonal Affective Disorder (SAD)1
4CompletedTreatmentSleep Deprivation1
4CompletedTreatmentSleeplessness2
4Not Yet RecruitingPreventionDelirium in Old Age1
4RecruitingPreventionDelirium1
4RecruitingTreatmentChronic Insomnia1
4RecruitingTreatmentLiver Cirrhosis1
4RecruitingTreatmentSchizophrenic Disorders1
4RecruitingTreatmentSleeplessness1
4TerminatedTreatmentChronic Insomnia1
4TerminatedTreatmentMigrainous Headache1
4TerminatedTreatmentParkinson's Disease (PD)1
4Unknown StatusTreatmentBrain Injury / Sleeplessness1
4Unknown StatusTreatmentSleeplessness1
4WithdrawnOtherDelirium1
Not AvailableCompletedNot AvailableSleeplessness2
Not AvailableCompletedBasic ScienceHealthy Volunteers1
Not AvailableCompletedDiagnosticObstructive Sleep Apnea (OSA)1
Not AvailableEnrolling by InvitationPreventionDelirium / Sleep Deprivation1
Not AvailableTerminatedTreatmentPain, Neuropathic1
Not AvailableTerminatedTreatmentPanic Disorders / Sleeplessness1
Not AvailableTerminatedTreatmentParkinsonism / REM Behavior Disorder1
Not AvailableWithdrawnTreatmentCircadian Dysregulation / Diffuse Lewy Body Disease / Huntington's Disease (HD) / Parkinson's Disease (PD) / Sleep disorders and disturbances1

Pharmacoeconomics

Manufacturers
  • Takeda global research development center inc
Packagers
  • Bryant Ranch Prepack
  • DispenseXpress Inc.
  • Innoviant Pharmacy Inc.
  • Physicians Total Care Inc.
  • Rebel Distributors Corp.
  • Southwood Pharmaceuticals
  • Takeda Pharmaceutical Co. Ltd.
Dosage forms
FormRouteStrength
Tablet, film coatedOral8 mg/1
Prices
Unit descriptionCostUnit
Rozerem 8 mg tablet5.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6034239No1999-07-222019-07-22Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0164 mg/mLALOGPS
logP3.03ALOGPS
logP2.57ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)15.82ChemAxon
pKa (Strongest Basic)-0.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity75.52 m3·mol-1ChemAxon
Polarizability29.99 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9934
Caco-2 permeable+0.5893
P-glycoprotein substrateSubstrate0.5211
P-glycoprotein inhibitor INon-inhibitor0.8548
P-glycoprotein inhibitor IINon-inhibitor0.7877
Renal organic cation transporterNon-inhibitor0.6381
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.6392
CYP450 3A4 substrateSubstrate0.512
CYP450 1A2 substrateInhibitor0.7314
CYP450 2C9 inhibitorNon-inhibitor0.6471
CYP450 2D6 inhibitorNon-inhibitor0.5916
CYP450 2C19 inhibitorInhibitor0.8314
CYP450 3A4 inhibitorNon-inhibitor0.9196
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7763
Ames testNon AMES toxic0.7016
CarcinogenicityNon-carcinogens0.8206
BiodegradationReady biodegradable0.6635
Rat acute toxicity2.1034 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7898
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0nmi-2980000000-5ee1e7ec83e5c4578dfe

Taxonomy

Description
This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Indanes
Sub Class
Not Available
Direct Parent
Indanes
Alternative Parents
Coumarans / Alkyl aryl ethers / Secondary carboxylic acid amides / Oxacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Indane / Coumaran / Alkyl aryl ether / Carboxamide group / Secondary carboxylic acid amide / Oxacycle / Organoheterocyclic compound / Ether / Carboxylic acid derivative / Hydrocarbon derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Multitarget
General Function
Organic cyclic compound binding
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1A
Uniprot ID
P48039
Uniprot Name
Melatonin receptor type 1A
Molecular Weight
39374.315 Da
References
  1. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10. [PubMed:15695169]
  2. Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265]
  3. Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96. [PubMed:17389558]
  4. Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650]
  5. Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24. [PubMed:16730121]
  6. Authors unspecified: Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8. [PubMed:15869323]
  7. Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178]
  8. Miyamoto M: [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. [PubMed:19768947]
  9. Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703]
  10. Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111]
  11. Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. [PubMed:17015817]
  12. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. [PubMed:17803013]
  13. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Multitarget
General Function
Melatonin receptor activity
Specific Function
High affinity receptor for melatonin. Likely to mediates the reproductive and circadian actions of melatonin. The activity of this receptor is mediated by pertussis toxin sensitive G proteins that ...
Gene Name
MTNR1B
Uniprot ID
P49286
Uniprot Name
Melatonin receptor type 1B
Molecular Weight
40187.895 Da
References
  1. Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, Kawamata Y, Hinuma S, Miyamoto M: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005 Feb;48(2):301-10. [PubMed:15695169]
  2. Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. [PubMed:16432265]
  3. Greenblatt DJ, Harmatz JS, Karim A: Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. J Clin Pharmacol. 2007 Apr;47(4):485-96. [PubMed:17389558]
  4. Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar;28(3):303-7. [PubMed:16173650]
  5. Miyamoto M: Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice. Neurosci Lett. 2006 Jul 24;402(3):201-4. Epub 2006 May 24. [PubMed:16730121]
  6. Authors unspecified: Ramelteon: TAK 375. Drugs R D. 2005;6(3):186-8. [PubMed:15869323]
  7. Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. doi: 10.1111/j.1755-5949.2008.00066.x. [PubMed:19228178]
  8. Miyamoto M: [A novel therapeutic drug: ramelteon]. Nihon Rinsho. 2009 Aug;67(8):1595-600. [PubMed:19768947]
  9. Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. doi: 10.1007/s12325-009-0041-6. Epub 2009 Jun 30. [PubMed:19568703]
  10. Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. [PubMed:17157111]
  11. Johnson MW, Suess PE, Griffiths RR: Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry. 2006 Oct;63(10):1149-57. [PubMed:17015817]
  12. Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang J, Roth T: Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007 Aug 15;3(5):495-504. [PubMed:17803013]
  13. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. doi: 10.1124/dmd.110.034009. Epub 2010 May 17. [PubMed:20478852]

Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 02:05